Combined effect of propranolol with nifedipine or with diltiazem on rat liver monooxygenase activities

Toxicology Letters

Volumn 105, Issue 2, 1999, Pages 153-161

  Koleva, M ^a   Kastelova, A ^a   Staneva Stoytcheva, D ^a   Stoytchev, Ts ^a  

^a INSTITUTE OF PHYSIOLOGY   (Bulgaria)

Author keywords

Cytochrome P 450; Diltiazem; Nifedipine; Propranolol; Rat liver monooxygenases

Indexed keywords

AMINOPYRINE N DEMETHYLASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CYTOCHROME B5; CYTOCHROME P450; DILTIAZEM; ETHYLMORPHINE N DEMETHYLASE; HEXOBARBITAL; NIFEDIPINE; PROPRANOLOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE FERRIHEMOPROTEIN REDUCTASE; UNSPECIFIC MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; LIVER METABOLISM; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SLEEP TIME;

ADRENERGIC BETA-ANTAGONISTS; AMINOPYRINE N-DEMETHYLASE; ANIMALS; CALCIUM CHANNEL BLOCKERS; CYTOCHROME P-450 ENZYME SYSTEM; CYTOCHROMES B5; DILTIAZEM; ETHYLMORPHINE-N-DEMETHYLASE; HEXOBARBITAL; HYPNOTICS AND SEDATIVES; LIVER; MALE; NADPH-FERRIHEMOPROTEIN REDUCTASE; NIFEDIPINE; PROPRANOLOL; RATS; RATS, WISTAR; SLEEP;

EID: 0033063635     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(98)00395-6     Document Type: Article

References (39)

1. Bax N.D.S., Lennard M.S., Al Asady S., Deacon C.S., Tucker G.T. Inhibition of drug metabolism by β-adrenoceptor antagonists. Drugs. 25(Suppl 2):1983;121-126.
2. Church J., Zsoter T. Calcium antagonistic drugs. Mechanism of action. Can. J. Physiol. Pharmacol. 58:1980;254-264.
3. Conrad K.A., Nyman D.W. Effect of metoprolol and propranolol on theophyline elimination. Clin. Pharm. Ther. 28:1980;463-467.
4. Dargie H.L. Combination therapy with beta adrenoceptor blockers and calcium antagonists. Br. J. Clin. Pharmacol. 21:1986;1555-1605.
5. Dimmitt D., Yu D., Elvin A., Giesing D. Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. Biopharm. Drug Dispos. 1:1991;515-523.
6. Fujita S., Umeda S., Funae Y., Imaoka S., Abe H., Ishida R., Adachi T., Masuda A., Kazusaka A., Suzuki T. Regio- and stereoselective propranolol metabolism by 15 forms of purified cytochromes P-450 from rat liver. J. Pharmacol. Exp. Ther. 264:1993;226-233.
7. Guengerich F.P. Microsomal enzymes involved in toxicology. Analysis and separation. Hayes A.W. Principles and methods of toxicology. 1982;609-634 Raven Press, New York.
8. Guengerich F.P., Martin M.V., Beaune P.H., Kremers P., Wolff T., Waxman D. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 261:1986;5051.
9. Guengerich F.P., Brian W.R., Iwasaki M., Sari M., Baarnhielm C., Bartsson P. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450IIIA4. J. Med. Chem. 34:1991;1838-1844.
10. Hunt B.A., Bottorff M.B., Herring V.L. Effects of calcium channel blockers on the pharmacokinetics of propranolol stereoisomers. Clin. Pharmacol. Ther. 47:1990;584-591.
11. Ishida R., Obara S., Masubuchi Y., Narimatsu S., Fujita S., Suzuki T. Induction of propranolol metabolism by the azo dye sudan III in rats. Biochem. Pharmacol. 41:1992;2489-2492.
12. Kastelova A., Stoytchev Ts. Effect of propranolol, pindolol and atenolol on drug-metabolizing enzyme systems after single administration in rats. Compt. Rend. Acad. Bulg. Sci. 46:1993;119-122.
13. Koleva M., Stoytchev Ts. Effect of nifedipine, verapamil and diltiazem on drug-metabolizing enzyme systems after single sdministration in rats. Compt. Rend. Acad. Bulg. Sci. 44:1991;109-111.
14. Levin M., Ogilvie R., Leenen F. Pharmacokinetic and pharmacodynamic interactions between nisoldipine and propranolol. Clin. Pharmacol. Ther. 43:1988;39-48.
15. Lydiane P., Gillet G., Fabre I., Dalet-Beluche I., Bonfils C., Thenor J.P., Maurel P. Identification of the rabbit and human cytochromes P-450IIIA as the major enzymes involved in the N-demethylation of diltiazem. Drug Metab. Dispos. 18:1990;711-719.
16. Masubuchi Y., Fujita S., Chiba M., Kugimato N., Umeda S., Suzuki T. Impairtment of debrisoquine 4-hydroxylase and related monooxygenase activities in the rat following treatment with propranolol. Biochem. Pharmacol. 41:1991;861-865.
17. Masubuchi Y., Suzuki K., Fujita S., Suzuki T. A possible mechanism of the impairtment of hepatic microsomal monooxigenase activities after multiple administration of propranolol in rats. Biochem. Pharmacol. 43(4):1992;757-762.
18. Masubuchi Y., Kagimoto N., Narimatsu S., Fujita S., Suzuki T. Regioselective contributionof the cytochrome P-450 2D subfamily to propranolol metabolism in rat liver microsomes. Drug Metab. Dispos. 21(6):1993;1012-1016.
19. Masubuchi Y., Hosokawa S., Horie T., Suzuki T., Ohmori S., Kitada M., Narimatsu S. Cytochrome P-450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxilase and CYP1A2 as N-desisopropylase. Drug Metab. Dispos. 22(6):1994b;909-915.
20. Masubuchi Y., Narimatsu S., Hosokawa S., Suzuki T. Role of the CYP2D subfamily in metabolism-dependent covalent binding of propranolol to liver microsomal protein in rats. Biochem. Pharmacol. 48(10):1994a;1891-1898.
21. Mazel P. Experiments illustrating drug metabolism in vitro. Determination of aniline hydroxylase. La Du B.H., Mandel H.G., Way E.L. Fundamentals of drug metabolism and drug disposition. 1972;569-572 Williams and Williams, Baltimore.
22. Narimatsu S., Monchida M., Matsumoto T., Masubuchi Y., Horie T., Nagata K., Funae Y., Cho A.K., Suzuki T. Cytochrome P-450 enzymes involved in the enchancement of propranolol N-desisopropilation after repeated administration of propranolol in rats. Chem.-Biol. Interact. 101(3):1996;207-224.
23. Narimatsu S., Watanabe T., Masubuchi Y., Horie T., Kumagai Y., Cho A.K., Imaoka S., Funae Y., Ishikawa T., Suzuki T. Characterization of a chemically reactive propranolol metabolite that binds to microsomal proteins of rat liver. Chem. Res. Toxicol. 8(5):1995;721-728.
24. Nash T. The colorimetric estimation of formaldehyde by means of the Hantzch reaction. J. Biol. Chem. 55:1953;412-416.
25. Nelson W., Olsen N. Regiochemistry and enantioselectivity in the oxidative N-dealkylation of verapamil. Drug Metab. Dispos. 16:1988;834-841.
26. Omura T., Sato R. The carbon monooxide binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239:1964;2370-2378.
27. Parker M. Combined beta adrenergic and calcium entry blockade in angina pectoris. New Engl. J. Med. 320:1989;709.
28. Renton K. Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil. Biochem. Pharmacol. 34:1985;2549-2553.
29. Scheneck D.W., Pritchared J.F. The inhibitory effect of propranolol pretreatment on its own metabolism in rats. J. Pharmacol. Exp. Ther. 218:1981;575-581.
30. Sies H., Graf P., Estrela J. Hepatic calcium efflux during cytochrome P-450 dependent drug oxidation at the endoplasmatic reticulum in intact liver. Proc. Natl. Acad. Sci. USA. 78:1981;3358-3362.
31. Suzuki T., Ishida R., Matsui S., Narimatsu S. Kinetic analysis of mutual metabolic inhibition of lidocaine and propranolol in rat liver microsomes. Biochem. Pharmacol. 45(7):1993;1528-1530.
32. Tateishi T., Nakashima H., Shitou T., Kumagai Y., Ohashi K, Hosoda S., Ebihara A. Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol. Eur. J. Clin. Pharmacol. 36:1989;67-70.
33. Vermilion J., Coon M. Purifed liver microsomal NADPH-cytochrome P-450 reductase. J. Biol. Chem. 253:1978;2694-2704.
34. Weishaar R.E., Quade M.M., Pugsley T.A., Shih Y.H., Taylor D.G. Interaction between propranolol and calcium channel blockers in cardiac and vascular smooth muscle. J. Mol. Cell. Cardiol. 20:1988;897.
35. Weitman S.D., Phelan A.M., Lech J.J., Lange D.G. Propranolol induced alterations in rat erythrocyte membrabne fluidity and apparent phase-transition temperatutes. Biochem. Pharmacol. 38:1989;2949-2954.
36. Wilkins M., Woods K., Jack D., Kendall M., Laugher S. Separate and combined effects of nadolol and nifedipine on the cardiac response to exercise. Eur. J. Clin. Pharmacol. 28:1985;113-117.
37. Yamazaki H., Nakano M., Imai Y., Ueng Y., Guengerich F., Shimada T. Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P-450 3A4 and by human liver microsomes. Arch. Biochem. Biophys. 2:1996;174-182.
38. Yoshimoto K., Echizen H., Chiba K., Tahi M., Ishizaki T. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers - N-desisopropylation is mediated mainly by CYP1A2. Br. J. Clin. Pharmacol. 39(4):1995;421-431.
39. Zylber-Katz E., Turetz-Abramovitch M., Koren G., Levy M. Pharmacokinetic interaction between nifedipine and propranolol. Fundam. Clin. Pharmacol. 2:1988;29-35.